Vascular endothelial growth factor receptor 2 — Drug Target

All drugs that target Vascular endothelial growth factor receptor 2 — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

Kinase Inhibitor · Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] · Kinase Inhibitor [EPC] · Anthelmintic [EPC]

Marketed (6)

• Cometriq · Exelixis · Kinase Inhibitor · Oncology
  Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis.
• Cyramza · Eli Lilly · Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] · Oncology
  Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread.
• Nexavar · Bayer · Kinase Inhibitor [EPC] · Oncology
• Vermox · Anthelmintic [EPC] · Infectious Disease
  Vermox works by interfering with the parasite's ability to absorb glucose, ultimately leading to its death.
• Cometriq · Exelixis Inc · Kinase Inhibitor · Oncology
  Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis.
• Rivoceranib · Zhongda Hospital · Oncology